Hematological Malignancies

SWOG: CHOP vs 3 intensive regimens in advanced NHL

Patients at risk 225

3-year estimate (%)

CHOP m-BACOD ProMACE-CytaBOM MACOP-B

100

54 52 50 50

223 233 218

80

p = 0.90

60

40

20

% of treatment group

0

0 2 4 6

Years after randomization

Fischer et al. NEJM 1993; 328: 1002–6